BioScrip, Inc. (NASDAQ: BIOS) reported Q2 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $247.1 million versus the consensus estimate of $233.7 million.

BioScrip, Inc. sees FY2014 revenue of $940-980 million, versus the consensus of $966.20 million.

For earnings history and earnings-related data on BioScrip, Inc. (BIOS) click here.